BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 11794218)

  • 1. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1.
    Gortmaker SL; Hughes M; Cervia J; Brady M; Johnson GM; Seage GR; Song LY; Dankner WM; Oleske JM;
    N Engl J Med; 2001 Nov; 345(21):1522-8. PubMed ID: 11794218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection.
    Storm DS; Boland MG; Gortmaker SL; He Y; Skurnick J; Howland L; Oleske JM;
    Pediatrics; 2005 Feb; 115(2):e173-82. PubMed ID: 15629958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral therapy during pregnancy and the risk of an adverse outcome.
    Tuomala RE; Shapiro DE; Mofenson LM; Bryson Y; Culnane M; Hughes MD; O'Sullivan MJ; Scott G; Stek AM; Wara D; Bulterys M
    N Engl J Med; 2002 Jun; 346(24):1863-70. PubMed ID: 12063370
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.
    Patel K; Hernán MA; Williams PL; Seeger JD; McIntosh K; Van Dyke RB; Seage GR;
    Clin Infect Dis; 2008 Feb; 46(4):507-15. PubMed ID: 18199042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
    Hammer SM; Squires KE; Hughes MD; Grimes JM; Demeter LM; Currier JS; Eron JJ; Feinberg JE; Balfour HH; Deyton LR; Chodakewitz JA; Fischl MA
    N Engl J Med; 1997 Sep; 337(11):725-33. PubMed ID: 9287227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of malnutrition in survival of HIV infected children after initiation of antiretroviral treatment (ART).
    Taye B; Shiferaw S; Enquselassie F
    Ethiop Med J; 2010 Jan; 48(1):1-10. PubMed ID: 20607992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. AIDS Clinical Trials Group (ACTG) Study 152 Team.
    Englund JA; Baker CJ; Raskino C; McKinney RE; Petrie B; Fowler MG; Pearson D; Gershon A; McSherry GD; Abrams EJ; Schliozberg J; Sullivan JL
    N Engl J Med; 1997 Jun; 336(24):1704-12. PubMed ID: 9182213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy.
    Viani RM; Araneta MR; Deville JG; Spector SA
    Clin Infect Dis; 2004 Sep; 39(5):725-31. PubMed ID: 15356789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
    Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
    N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.
    Deeks SG; Wrin T; Liegler T; Hoh R; Hayden M; Barbour JD; Hellmann NS; Petropoulos CJ; McCune JM; Hellerstein MK; Grant RM
    N Engl J Med; 2001 Feb; 344(7):472-80. PubMed ID: 11172188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute pancreatitis associated with different combination therapies in patients infected with human immunodeficiency virus.
    Guo JJ; Jang R; Louder A; Cluxton RJ
    Pharmacotherapy; 2005 Aug; 25(8):1044-54. PubMed ID: 16207094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with mortality in human immunodeficiency virus type 1-infected adults initiating protease inhibitor-containing therapy: role of education level and of early transaminase level elevation (APROCO-ANRS EP11 study). The Antiprotéases Cohorte Agence Nationale de Recherches sur le SIDA EP 11 study.
    Lewden C; Raffi F; Cuzin L; Cailleton V; Vildé JL; Chêne G; Allavena C; Salamon R; Leport C
    J Infect Dis; 2002 Sep; 186(5):710-4. PubMed ID: 12195361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.
    Bozzette SA; Ake CF; Tam HK; Chang SW; Louis TA
    N Engl J Med; 2003 Feb; 348(8):702-10. PubMed ID: 12594314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens.
    Hogg RS; Yip B; Kully C; Craib KJ; O'Shaughnessy MV; Schechter MT; Montaner JS
    CMAJ; 1999 Mar; 160(5):659-65. PubMed ID: 10102000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human immunodeficiency virus type 1 protease genotype predicts immune and viral responses to combination therapy with protease inhibitors (PIs) in PI-naive patients.
    Perez EE; Rose SL; Peyser B; Lamers SL; Burkhardt B; Dunn BM; Hutson AD; Sleasman JW; Goodenow MM
    J Infect Dis; 2001 Feb; 183(4):579-88. PubMed ID: 11170983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy].
    Jambroes M; Weverling GJ; Reiss P; Danner SA; Jurriaans S; ten Veen JH; van der Ende ME; Schutten M; Schneider MM; Schuurman R; Mulder JW; Kroes AC; Lange JM; de Wolf F;
    Ned Tijdschr Geneeskd; 2001 Aug; 145(33):1591-7. PubMed ID: 11534377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4 cell response to antiretroviral therapy in children with vertically acquired HIV infection: is it associated with age at initiation?
    Newell ML; Patel D; Goetghebuer T; Thorne C;
    J Infect Dis; 2006 Apr; 193(7):954-62. PubMed ID: 16518757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate.
    Krogstad P; Wiznia A; Luzuriaga K; Dankner W; Nielsen K; Gersten M; Kerr B; Hendricks A; Boczany B; Rosenberg M; Jung D; Spector SA; Bryson Y
    Clin Infect Dis; 1999 May; 28(5):1109-18. PubMed ID: 10452644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
    Hoffmann F; Funk M; Linde R; Notheis G; Petropoulou T; Eberle J; Gürtler L; Belohradsky BH; Wintergerst U
    Eur J Med Res; 2002 Jul; 7(7):330-4. PubMed ID: 12176683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.